Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 546 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... September 26, 2022 Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... June 30, 2022 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Registered Dietitian vs. Nutritionist March 3, 2021 Load more HOT NEWS How to Cope With Waiting Periods During Cancer: An Expert Perspective HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March Exercising Safely During Breast Cancer Treatment: What to Know